“We have shown Blautix to be safe and well tolerated,” said chief executive Duncan Peyton.
“This trial is providing patient samples that will give the company a better understanding of what is happening in IBS patients undergoing the treatment of Blautix.”
4D is now analysing the samples and data from the trials in greater detail to help develop its understanding of Blautix and to help design the next round of trials.
Phase I trials assess the safety of the drug. The next stage, phase II, is the first test of a new treatment’s efficacy.
Shares rose 19.5p or 2.4% to 850p.